Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-CART in Refractory or Recurrent ALL
NCT02186860Phase 1Unknown
- Sponsor
- Academy of Military Medical Sciences
- Start
- Jul 2016
- Primary completion
- Oct 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19 CAR-T cells in acute lymphoblastic leukemia (ALL), sponsored by Academy of Military Medical Sciences. Primary endpoint: Number of Adverse Events at 8 weeks. Status: unknown.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02186860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02186860.